{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:35:03Z","timestamp":1792672503745,"version":"4.5.0"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41579-024-01008-2","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T07:02:51Z","timestamp":1707202971000},"page":"373-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-7622","authenticated-orcid":false,"given":"Philip J.","family":"Rosenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4692","authenticated-orcid":false,"given":"Victor","family":"Asua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-8030","authenticated-orcid":false,"given":"Melissa D.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"1008_CR1","unstructured":"World Health Organization. World Malaria Report (WHO, 2022)."},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrmicro.2017.161","volume":"16","author":"K Haldar","year":"2018","unstructured":"Haldar, K., Bhattacharjee, S. & Safeukui, I. Drug resistance in Plasmodium. Nat. Rev. Microbiol. 16, 156\u2013170 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"1008_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04115-8","volume":"21","author":"CV Plowe","year":"2022","unstructured":"Plowe, C. V. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar. J. 21, 104 (2022).","journal-title":"Malar. J."},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.mib.2022.102193","volume":"69","author":"KE Ward","year":"2022","unstructured":"Ward, K. E., Fidock, D. A. & Bridgford, J. L. Plasmodium falciparum resistance to artemisinin-based combination therapies. Curr. Opin. Microbiol. 69, 102193 (2022).","journal-title":"Curr. Opin. Microbiol."},{"key":"1008_CR5","unstructured":"World Health Organization. WHO Guidelines for Malaria (WHO, 2022)."},{"key":"1008_CR6","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl, H., Se, Y., Schaecher, K., Smith, B. L., Socheat, D. & Fukuda, M. M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359, 2619\u20132620 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455\u2013467 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S1473-3099(19)30261-0","volume":"19","author":"MD Conrad","year":"2019","unstructured":"Conrad, M. D. & Rosenthal, P. J. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect. Dis. 19, e338\u2013e351 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nm.2471","volume":"17","author":"Y Tu","year":"2011","unstructured":"Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17, 1217\u20131220 (2011).","journal-title":"Nat. Med."},{"key":"1008_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1126\/science.3887571","volume":"228","author":"DL Klayman","year":"1985","unstructured":"Klayman, D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049\u20131055 (1985).","journal-title":"Science"},{"key":"1008_CR11","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.1155165","volume":"320","author":"NJ White","year":"2008","unstructured":"White, N. J. Qinghaosu (artemisinin): the price of success. Science 320, 330\u2013334 (2008).","journal-title":"Science"},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2011.08.024","volume":"146","author":"LH Miller","year":"2011","unstructured":"Miller, L. H. & Su, X. Artemisinin: discovery from the Chinese herbal garden. Cell 146, 855\u2013858 (2011).","journal-title":"Cell"},{"key":"1008_CR13","doi-asserted-by":"publisher","first-page":"107658","DOI":"10.1016\/j.pharmthera.2020.107658","volume":"216","author":"N Ma","year":"2020","unstructured":"Ma, N., Zhang, Z., Liao, F., Jiang, T. & Tu, Y. The birth of artemisinin. Pharmacol. Ther. 216, 107658 (2020).","journal-title":"Pharmacol. Ther."},{"key":"1008_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736(82)90268-9","volume":"2","author":"JB Jiang","year":"1982","unstructured":"Jiang, J. B., Li, G. Q., Guo, X. B., Kong, Y. C. & Arnold, K. Antimalarial activity of mefloquine and qinghaosu. Lancet 2, 285\u2013288 (1982).","journal-title":"Lancet"},{"key":"1008_CR15","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S0140-6736(84)92057-9","volume":"2","author":"GQ Li","year":"1984","unstructured":"Li, G. Q., Arnold, K., Guo, X. B., Jian, H. X. & Fu, L. C. Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. Lancet 2, 1360\u20131361 (1984).","journal-title":"Lancet"},{"key":"1008_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4269\/ajtmh.2007.77.181","volume":"77","author":"F Nosten","year":"2007","unstructured":"Nosten, F. & White, N. J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77, 181\u2013192 (2007).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/infdis\/170.4.971","volume":"170","author":"F Nosten","year":"1994","unstructured":"Nosten, F. et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J. Infect. Dis. 170, 971\u2013977 (1994).","journal-title":"J. Infect. Dis."},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0140-6736(00)02505-8","volume":"356","author":"F Nosten","year":"2000","unstructured":"Nosten, F. et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297\u2013302 (2000).","journal-title":"Lancet"},{"key":"1008_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price, R. N. et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438\u2013447 (2004).","journal-title":"Lancet"},{"key":"1008_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.4269\/ajtmh.1999.60.936","volume":"60","author":"MV Vugt","year":"1999","unstructured":"Vugt, M. V. et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 60, 936\u2013942 (1999).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","volume":"391","author":"West African Network for Clinical Trials of Antimalarial Drugs (WANECAM).","year":"2018","unstructured":"West African Network for Clinical Trials of Antimalarial Drugs (WANECAM). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial. Lancet 391, 1378\u20131390 (2018).","journal-title":"Lancet"},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(05)67176-0","volume":"366","author":"A Dondorp","year":"2005","unstructured":"Dondorp, A., Nosten, F., Stepniewska, K., Day, N. & White, N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, 717\u2013725 (2005).","journal-title":"Lancet"},{"key":"1008_CR23","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","volume":"376","author":"AM Dondorp","year":"2010","unstructured":"Dondorp, A. M. et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376, 1647\u20131657 (2010).","journal-title":"Lancet"},{"key":"1008_CR24","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0020-7519(02)00194-7","volume":"32","author":"SR Meshnick","year":"2002","unstructured":"Meshnick, S. R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32, 1655\u20131660 (2002).","journal-title":"Int. J. Parasitol."},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0166-6851(96)02763-6","volume":"83","author":"PJ Rosenthal","year":"1996","unstructured":"Rosenthal, P. J. & Meshnick, S. R. Hemoglobin catabolism and iron utilization by malaria parasites. Mol. Biochem. Parasitol. 83, 131\u2013139 (1996).","journal-title":"Mol. Biochem. Parasitol."},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev-micro-091313-103537","volume":"68","author":"PA Sigala","year":"2014","unstructured":"Sigala, P. A. & Goldberg, D. E. The peculiarities and paradoxes of Plasmodium heme metabolism. Annu. Rev. Microbiol. 68, 259\u2013278 (2014).","journal-title":"Annu. Rev. Microbiol."},{"key":"1008_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/tropicalmed4020089","volume":"4","author":"LE Heller","year":"2019","unstructured":"Heller, L. E. & Roepe, P. D. Artemisinin-based antimalarial drug therapy: molecular pharmacology and evolving resistance. Trop. Med. Infect. Dis. 4, 89 (2019).","journal-title":"Trop. Med. Infect. Dis."},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"11405","DOI":"10.1073\/pnas.1104063108","volume":"108","author":"N Klonis","year":"2011","unstructured":"Klonis, N. et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc. Natl Acad. Sci. USA 108, 11405\u201311410 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1008_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10111","volume":"6","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat. Commun. 6, 10111 (2015).","journal-title":"Nat. Commun."},{"key":"1008_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06221-1","volume":"9","author":"JL Bridgford","year":"2018","unstructured":"Bridgford, J. L. et al. Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat. Commun. 9, 3801 (2018).","journal-title":"Nat. Commun."},{"key":"1008_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/QCO.0000000000000766","volume":"34","author":"M Dhorda","year":"2021","unstructured":"Dhorda, M., Amaratunga, C. & Dondorp, A. M. Artemisinin and multidrug-resistant Plasmodium falciparum \u2014 a threat for malaria control and elimination. Curr. Opin. Infect. Dis. 34, 432\u2013439 (2021).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"1008_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","volume":"13","author":"B Witkowski","year":"2013","unstructured":"Witkowski, B. et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect. Dis. 13, 1043\u20131049 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50\u201355 (2014).","journal-title":"Nature"},{"key":"1008_CR34","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.1260867","volume":"347","author":"J Straimer","year":"2015","unstructured":"Straimer, J. et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347, 428\u2013431 (2015).","journal-title":"Science"},{"key":"1008_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3","volume":"17","author":"WWARN K13 Genotype-Phenotype Study Group.","year":"2019","unstructured":"WWARN K13 Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis. BMC Med. 17, 1 (2019).","journal-title":"BMC Med."},{"key":"1008_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng.3189","volume":"47","author":"O Miotto","year":"2015","unstructured":"Miotto, O. et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat. Genet. 47, 226\u2013234 (2015).","journal-title":"Nat. Genet."},{"key":"1008_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01320-21","volume":"66","author":"L Paloque","year":"2022","unstructured":"Paloque, L. et al. Mutation in the Plasmodium falciparum BTB\/POZ domain of K13 protein confers artemisinin resistance. Antimicrob. Agents Chemother. 66, e0132021 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41579-019-0238-x","volume":"17","author":"MP Barrett","year":"2019","unstructured":"Barrett, M. P., Kyle, D. E., Sibley, L. D., Radke, J. B. & Tarleton, R. L. Protozoan persister-like cells and drug treatment failure. Nat. Rev. Microbiol. 17, 607\u2013620 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1008_CR39","doi-asserted-by":"publisher","first-page":"fuaa056","DOI":"10.1093\/femsre\/fuaa056","volume":"45","author":"CJ Sutherland","year":"2021","unstructured":"Sutherland, C. J., Henrici, R. C. & Artavanis-Tsakonas, K. Artemisinin susceptibility in the malaria parasite Plasmodium falciparum: propellers, adaptor proteins and the need for cellular healing. FEMS Microbiol. Rev. 45, fuaa056 (2021).","journal-title":"FEMS Microbiol. Rev."},{"key":"1008_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijpddr.2021.05.007","volume":"16","author":"FA Siddiqui","year":"2021","unstructured":"Siddiqui, F. A., Liang, X. & Cui, L. Plasmodium falciparum resistance to ACTs: emergence, mechanisms, and outlook. Int. J. Parasitol. Drugs Drug Resist. 16, 102\u2013118 (2021).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"1008_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1126\/science.1260403","volume":"347","author":"S Mok","year":"2015","unstructured":"Mok, S. et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347, 431\u2013435 (2015).","journal-title":"Science"},{"key":"1008_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20805-w","volume":"12","author":"S Mok","year":"2021","unstructured":"Mok, S. et al. Artemisinin-resistant K13 mutations rewire Plasmodium falciparum\u2019s intra-erythrocytic metabolic program to enhance survival. Nat. Commun. 12, 530 (2021).","journal-title":"Nat. Commun."},{"key":"1008_CR43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s42003-022-03215-0","volume":"5","author":"L Zhu","year":"2022","unstructured":"Zhu, L. et al. Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Commun. Biol. 5, 274 (2022).","journal-title":"Commun. Biol."},{"key":"1008_CR44","doi-asserted-by":"publisher","first-page":"107996","DOI":"10.1016\/j.celrep.2020.107996","volume":"32","author":"A Xiong","year":"2020","unstructured":"Xiong, A. et al. K13-mediated reduced susceptibility to artemisinin in Plasmodium falciparum Is overlaid on a trait of enhanced DNA damage repair. Cell Rep. 32, 107996 (2020).","journal-title":"Cell Rep."},{"key":"1008_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00753-21","volume":"12","author":"SV Connelly","year":"2021","unstructured":"Connelly, S. V. et al. Restructured mitochondrial-nuclear interaction in Plasmodium falciparum dormancy and persister survival after artemisinin exposure. mBio 12, e0075321 (2021).","journal-title":"mBio"},{"key":"1008_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nature14412","volume":"520","author":"A Mbengue","year":"2015","unstructured":"Mbengue, A. et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520, 683\u2013687 (2015).","journal-title":"Nature"},{"key":"1008_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1126\/science.aax4735","volume":"367","author":"J Birnbaum","year":"2020","unstructured":"Birnbaum, J. et al. A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites. Science 367, 51\u201359 (2020).","journal-title":"Science"},{"key":"1008_CR48","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/infdis\/jix156","volume":"215","author":"G Siddiqui","year":"2017","unstructured":"Siddiqui, G., Srivastava, A., Russell, A. S. & Creek, D. J. Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin-resistant Plasmodium falciparum. J. Infect. Dis. 215, 1435\u20131444 (2017).","journal-title":"J. Infect. Dis."},{"key":"1008_CR49","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1016\/j.celrep.2019.10.095","volume":"29","author":"T Yang","year":"2019","unstructured":"Yang, T. et al. Decreased K13 abundance reduces hemoglobin catabolism and proteotoxic stress, underpinning artemisinin resistance. Cell Rep. 29, 2917\u20132928.e5 (2019).","journal-title":"Cell Rep."},{"key":"1008_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008482","volume":"16","author":"NF Gnadig","year":"2020","unstructured":"Gnadig, N. F. et al. Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13. PLoS Pathog. 16, e1008482 (2020).","journal-title":"PLoS Pathog."},{"key":"1008_CR51","first-page":"406","volume":"129","author":"SC Xie","year":"2016","unstructured":"Xie, S. C. et al. Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. J. Cell Sci. 129, 406\u2013416 (2016).","journal-title":"J. Cell Sci."},{"key":"1008_CR52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.66277","volume":"10","author":"BH Stokes","year":"2021","unstructured":"Stokes, B. H. et al. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. eLife 10, e66277 (2021).","journal-title":"eLife"},{"key":"1008_CR53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.pt.2020.03.006","volume":"36","author":"SC Xie","year":"2020","unstructured":"Xie, S. C., Ralph, S. A. & Tilley, L. K13, the cytostome, and artemisinin resistance. Trends Parasitol. 36, 533\u2013544 (2020).","journal-title":"Trends Parasitol."},{"key":"1008_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2958.2007.05753.x","volume":"65","author":"P Hunt","year":"2007","unstructured":"Hunt, P. et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol. Microbiol. 65, 27\u201340 (2007).","journal-title":"Mol. Microbiol."},{"key":"1008_CR55","doi-asserted-by":"publisher","first-page":"e02484-19","DOI":"10.1128\/AAC.02484-19","volume":"64","author":"NV Simwela","year":"2020","unstructured":"Simwela, N. V., Hughes, K. R., Roberts, A. B., Rennie, M. T., Barrett, M. P. & Waters, A. P. Experimentally engineered mutations in a ubiquitin hydrolase, UBP-1, modulate in vivo susceptibility to artemisinin and chloroquine in Plasmodium berghei. Antimicrob. Agents Chemother. 64, e02484-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR56","doi-asserted-by":"publisher","first-page":"e01542-19","DOI":"10.1128\/AAC.01542-19","volume":"64","author":"RC Henrici","year":"2019","unstructured":"Henrici, R. C., van Schalkwyk, D. A. & Sutherland, C. J. Modification of pfap2mu and pfubp1 markedly reduces ring-stage susceptibility of Plasmodium falciparum to artemisinin in vitro. Antimicrob. Agents Chemother. 64, e01542-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR57","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/infdis\/jiu358","volume":"210","author":"G Henriques","year":"2014","unstructured":"Henriques, G. et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J. Infect. Dis. 210, 2001\u20132008 (2014).","journal-title":"J. Infect. Dis."},{"key":"1008_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze, P. K. et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat. Commun. 13, 6353 (2022).","journal-title":"Nat. Commun."},{"key":"1008_CR59","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1128\/AAC.04067-14","volume":"59","author":"G Henriques","year":"2015","unstructured":"Henriques, G. et al. The Mu subunit of Plasmodium falciparum clathrin-associated adaptor protein 2 modulates in vitro parasite response to artemisinin and quinine. Antimicrob. Agents Chemother. 59, 2540\u20132547 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0801-5","volume":"14","author":"MA Olshina","year":"2015","unstructured":"Olshina, M. A. et al. Plasmodium falciparum coronin organizes arrays of parallel actin filaments potentially guiding directional motility in invasive malaria parasites. Malar. J. 14, 280 (2015).","journal-title":"Malar. J."},{"key":"1008_CR61","doi-asserted-by":"publisher","first-page":"12799","DOI":"10.1073\/pnas.1812317115","volume":"115","author":"AR Demas","year":"2018","unstructured":"Demas, A. R. et al. Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility. Proc. Natl Acad. Sci. USA 115, 12799\u201312804 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1008_CR62","doi-asserted-by":"publisher","first-page":"140362","DOI":"10.1016\/j.bbapap.2020.140362","volume":"1868","author":"PJ Rosenthal","year":"2020","unstructured":"Rosenthal, P. J. Falcipain cysteine proteases of malaria parasites: an update. Biochim. Biophys. Acta Proteins Proteom. 1868, 140362 (2020).","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"1008_CR63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/infdis\/jiy188","volume":"218","author":"FA Siddiqui","year":"2018","unstructured":"Siddiqui, F. A. et al. Plasmodium falciparum falcipain-2a polymorphisms in Southeast Asia and their association with artemisinin resistance. J. Infect. Dis. 218, 434\u2013442 (2018).","journal-title":"J. Infect. Dis."},{"key":"1008_CR64","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tips.2017.03.007","volume":"38","author":"J Wang","year":"2017","unstructured":"Wang, J., Xu, C., Lun, Z. R. & Meshnick, S. R. Unpacking \u2018artemisinin resistance\u2019. Trends Pharmacol. Sci. 38, 506\u2013511 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"1008_CR65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411\u2013423 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR66","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/cid\/ciw388","volume":"63","author":"AP Phyo","year":"2016","unstructured":"Phyo, A. P. et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): the role of parasite genetic factors. Clin. Infect. Dis. 63, 784\u2013791 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"1008_CR67","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga, C. et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect. Dis. 16, 357\u2013365 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR68","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/cid\/ciaa628","volume":"73","author":"M Mairet-Khedim","year":"2021","unstructured":"Mairet-Khedim, M. et al. Clinical and in vitro resistance of Plasmodium falciparum to artesunate-amodiaquine in Cambodia. Clin. Infect. Dis. 73, 406\u2013413 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"1008_CR69","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1016\/S2666-5247(21)00249-4","volume":"3","author":"FM Kagoro","year":"2022","unstructured":"Kagoro, F. M. et al. Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Lancet Microbe 3, e184\u2013e192 (2022).","journal-title":"Lancet Microbe"},{"key":"1008_CR70","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","volume":"211","author":"S Takala-Harrison","year":"2015","unstructured":"Takala-Harrison, S. et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J. Infect. Dis. 211, 670\u2013679 (2015).","journal-title":"J. Infect. Dis."},{"key":"1008_CR71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","volume":"18","author":"R Amato","year":"2018","unstructured":"Amato, R. et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect. Dis. 18, 337\u2013345 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR72","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","volume":"19","author":"WL Hamilton","year":"2019","unstructured":"Hamilton, W. L. et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect. Dis. 19, 943\u2013951 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR73","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S1473-3099(20)30228-0","volume":"20","author":"M Imwong","year":"2020","unstructured":"Imwong, M. et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect. Dis. 20, 1470\u20131480 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR74","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1473-3099(22)00697-1","volume":"23","author":"V Wasakul","year":"2023","unstructured":"Wasakul, V. et al. Malaria outbreak in Laos driven by a selective sweep for Plasmodium falciparum kelch13 R539T mutants: a genetic epidemiology analysis. Lancet Infect. Dis. 23, 568\u2013577 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR75","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/infdis\/jiv752","volume":"213","author":"SM Chenet","year":"2016","unstructured":"Chenet, S. M. et al. Independent emergence of the Plasmodium falciparum kelch Propeller domain mutant allele C580Y in Guyana. J. Infect. Dis. 213, 1472\u20131475 (2016).","journal-title":"J. Infect. Dis."},{"key":"1008_CR76","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.51015","volume":"9","author":"LC Mathieu","year":"2020","unstructured":"Mathieu, L. C. et al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. eLife 9, e51015 (2020).","journal-title":"eLife"},{"key":"1008_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009133","volume":"16","author":"O Miotto","year":"2020","unstructured":"Miotto, O. et al. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathog. 16, e1009133 (2020).","journal-title":"PLoS Pathog."},{"key":"1008_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03933-6","volume":"20","author":"N Yoshida","year":"2021","unstructured":"Yoshida, N., Yamauchi, M., Morikawa, R., Hombhanje, F. & Mita, T. Increase in the proportion of Plasmodium falciparum with kelch13 C580Y mutation and decline in pfcrt and pfmdr1 mutant alleles in Papua New Guinea. Malar. J. 20, 410 (2021).","journal-title":"Malar. J."},{"key":"1008_CR79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijpddr.2021.06.004","volume":"16","author":"D Lautu-Gumal","year":"2021","unstructured":"Lautu-Gumal, D. et al. Surveillance of molecular markers of Plasmodium falciparum artemisinin resistance (kelch13 mutations) in Papua New Guinea between 2016 and 2018. Int. J. Parasitol. Drugs Drug Resist. 16, 188\u2013193 (2021).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"1008_CR80","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1056\/NEJMc1713777","volume":"379","author":"S Das","year":"2018","unstructured":"Das, S., Saha, B., Hati, A. K. & Roy, S. Evidence of artemisinin-resistant Plasmodium falciparum malaria in eastern India. N. Engl. J. Med. 379, 1962\u20131964 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR81","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/cid\/ciy1038","volume":"69","author":"S Das","year":"2019","unstructured":"Das, S., Manna, S., Saha, B., Hati, A. K. & Roy, S. Novel pfkelch13 gene polymorphism associates With artemisinin resistance in eastern India. Clin. Infect. Dis. 69, 1144\u20131152 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1008_CR82","doi-asserted-by":"publisher","first-page":"8475246","DOI":"10.1155\/2020\/8475246","volume":"2020","author":"R Rana","year":"2020","unstructured":"Rana, R. et al. Sequence analysis of the K13-propeller gene in artemisinin challenging Plasmodium falciparum isolates from malaria endemic areas of Odisha, India: a molecular surveillance study. Biomed. Res. Int. 2020, 8475246 (2020).","journal-title":"Biomed. Res. Int."},{"key":"1008_CR83","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.4269\/ajtmh.18-0549","volume":"99","author":"J Wedam","year":"2018","unstructured":"Wedam, J. et al. Molecular evidence for Plasmodium falciparum resistance to sulfadoxine-pyrimethamine but absence of K13 mutations in Mangaluru, southwestern India. Am. J. Trop. Med. Hyg. 99, 1508\u20131510 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR84","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D Menard","year":"2016","unstructured":"Menard, D. et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N. Engl. J. Med. 374, 2453\u20132464 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR85","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/infdis\/jiu467","volume":"211","author":"SM Taylor","year":"2015","unstructured":"Taylor, S. M. et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J. Infect. Dis. 211, 680\u2013688 (2015).","journal-title":"J. Infect. Dis."},{"key":"1008_CR86","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau, E. et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J. Infect. Dis. 211, 1352\u20131355 (2015).","journal-title":"J. Infect. Dis."},{"key":"1008_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105690","volume":"9","author":"MD Conrad","year":"2014","unstructured":"Conrad, M. D. et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE 9, e105690 (2014).","journal-title":"PLoS ONE"},{"key":"1008_CR88","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1128\/AAC.00921-15","volume":"59","author":"RA Cooper","year":"2015","unstructured":"Cooper, R. A. et al. Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrob. Agents Chemother. 59, 5061\u20135064 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijpddr.2021.06.001","volume":"16","author":"L Ndwiga","year":"2021","unstructured":"Ndwiga, L. et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int. J. Parasitol. Drugs Drug Resist. 16, 155\u2013161 (2021).","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"1008_CR90","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4269\/ajtmh.16-0483","volume":"95","author":"C Tacoli","year":"2016","unstructured":"Tacoli, C. et al. Artemisinin resistance-associated K13 polymorphisms of Plasmodium falciparum in southern Rwanda, 2010-2015. Am. J. Trop. Med. Hyg. 95, 1090\u20131093 (2016).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR91","doi-asserted-by":"publisher","first-page":"ofad149","DOI":"10.1093\/ofid\/ofad149","volume":"10","author":"R Kirby","year":"2023","unstructured":"Kirby, R. et al. Examining the early distribution of the artemisinin-resistant Plasmodium falciparum kelch13 R561H mutation in areas of higher transmission in Rwanda. Open Forum Infect. Dis. 10, ofad149 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"1008_CR92","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602\u20131608 (2020).","journal-title":"Nat. Med."},{"key":"1008_CR93","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana, A. et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect. Dis. 21, 1120\u20131128 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR94","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer, J., Gandhi, P., Renner, K. C. & Schmitt, E. K. High prevalence of Plasmodium falciparum K13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J. Infect. Dis. 225, 1411\u20131414 (2022).","journal-title":"J. Infect. Dis."},{"key":"1008_CR95","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann, C. et al. Increase in Kelch 13 polymorphisms in Plasmodium falciparum, southern Rwanda. Emerg. Infect. Dis. 27, 294\u2013296 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"1008_CR96","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/mec.15706","volume":"30","author":"KA Moser","year":"2021","unstructured":"Moser, K. A. et al. Describing the current status of Plasmodium falciparum population structure and drug resistance within mainland Tanzania using molecular inversion probes. Mol. Ecol. 30, 100\u2013113 (2021).","journal-title":"Mol. Ecol."},{"key":"1008_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60549-7","volume":"10","author":"GM Bwire","year":"2020","unstructured":"Bwire, G. M., Ngasala, B., Mikomangwa, W. P., Kilonzi, M. & Kamuhabwa, A. A. R. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci. Rep. 10, 3500 (2020).","journal-title":"Sci. Rep."},{"key":"1008_CR98","doi-asserted-by":"publisher","unstructured":"Juliano, J. J. et al. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. Preprint at: medRxiv https:\/\/doi.org\/10.1101\/2023.11.07.23298207 (2023).","DOI":"10.1101\/2023.11.07.23298207"},{"key":"1008_CR99","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa2211803","volume":"389","author":"MD Conrad","year":"2023","unstructured":"Conrad, M. D. et al. Evolution of partial resistance to artemisinins in malaria parasites in Uganda. N. Engl. J. Med. 389, 722\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR100","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2210956","volume":"389","author":"S Mihreteab","year":"2023","unstructured":"Mihreteab, S. et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N. Engl. J. Med. 389, 1191\u20131202 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR101","first-page":"631","volume":"215","author":"P Tumwebaze","year":"2017","unstructured":"Tumwebaze, P. et al. Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. J. Infect. Dis. 215, 631\u2013635 (2017).","journal-title":"J. Infect. Dis."},{"key":"1008_CR102","doi-asserted-by":"publisher","first-page":"e01516-17","DOI":"10.1128\/AAC.01516-17","volume":"61","author":"SA Rasmussen","year":"2017","unstructured":"Rasmussen, S. A. et al. Changing antimalarial drug sensitivities in Uganda. Antimicrob. Agents Chemother. 61, e01516-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR103","doi-asserted-by":"publisher","first-page":"e01234-19","DOI":"10.1128\/AAC.01234-19","volume":"63","author":"MD Conrad","year":"2019","unstructured":"Conrad, M. D., Nsobya, S. L. & Rosenthal, P. J. The diversity of the Plasmodium falciparum K13 propeller domain did not increase after implementation of artemisinin-based combination therapy in Uganda. Antimicrob. Agents Chemother. 63, e01234-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR104","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3201\/eid2404.170141","volume":"24","author":"M Ikeda","year":"2018","unstructured":"Ikeda, M. et al. Artemisinin-resistant Plasmodium falciparum with high survival rates, Uganda, 2014-2016. Emerg. Infect. Dis. 24, 718\u2013726 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"1008_CR105","doi-asserted-by":"publisher","first-page":"e01818-18","DOI":"10.1128\/AAC.01818-18","volume":"63","author":"V Asua","year":"2019","unstructured":"Asua, V. et al. Changing molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob. Agents Chemother. 63, e01818-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR106","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua, V. et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J. Infect. Dis. 223, 985\u2013994 (2021).","journal-title":"J. Infect. Dis."},{"key":"1008_CR107","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR108","doi-asserted-by":"publisher","first-page":"e02550-18","DOI":"10.1128\/AAC.02550-18","volume":"63","author":"MA Pacheco","year":"2019","unstructured":"Pacheco, M. A. et al. Evolution and genetic diversity of the k13 gene associated with artemisinin delayed parasite clearance in Plasmodium falciparum. Antimicrob. Agents Chemother. 63, e02550-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR109","doi-asserted-by":"publisher","first-page":"e00802-19","DOI":"10.1128\/AAC.00802-19","volume":"63","author":"SA Matrevi","year":"2019","unstructured":"Matrevi, S. A. et al. Plasmodium falciparum kelch propeller polymorphisms in clinical isolates from Ghana from 2007 to 2016. Antimicrob. Agents Chemother. 63, e00802-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR110","doi-asserted-by":"publisher","first-page":"e01423-19","DOI":"10.1128\/AAC.01423-19","volume":"64","author":"BA Mensah","year":"2020","unstructured":"Mensah, B. A. et al. Antimalarial drug resistance profiling of Plasmodium falciparum infections in Ghana using molecular inversion probes and next-generation sequencing. Antimicrob. Agents Chemother. 64, e01423-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR111","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4269\/ajtmh.15-0477","volume":"94","author":"AG Bayih","year":"2016","unstructured":"Bayih, A. G., Getnet, G., Alemu, A., Getie, S., Mohon, A. N. & Pillai, D. R. A unique Plasmodium falciparum K13 gene mutation in northwest Ethiopia. Am. J. Trop. Med. Hyg. 94, 132\u2013135 (2016).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR112","doi-asserted-by":"publisher","unstructured":"Alemayehu, A. A. et al. Expansion of the Plasmodium falciparum Kelch 13 R622I mutation in Northwest Ethiopia. Preprint at: Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-171038\/v1 (2021).","DOI":"10.21203\/rs.3.rs-171038\/v1"},{"key":"1008_CR113","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41591-023-02641-9","volume":"29","author":"T Emiru","year":"2023","unstructured":"Emiru, T. et al. Evidence for a role of Anopheles stephensi in the spread of drug and diagnosis-resistant malaria in Africa. Nat. Med. 29, 3203\u20133211 (2023).","journal-title":"Nat. Med."},{"key":"1008_CR114","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola, A. A. et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat. Microbiol. 8, 1911\u20131919 (2023).","journal-title":"Nat. Microbiol."},{"key":"1008_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03987-6","volume":"20","author":"A Owoloye","year":"2021","unstructured":"Owoloye, A., Olufemi, M., Idowu, E. T. & Oyebola, K. M. Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum. Malar. J. 20, 451 (2021).","journal-title":"Malar. J."},{"key":"1008_CR116","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3201\/eid2804.212269","volume":"28","author":"W van Loon","year":"2022","unstructured":"van Loon, W. et al. In vitro confirmation of artemisinin resistance in Plasmodium falciparum from patient isolates, Southern Rwanda, 2019. Emerg. Infect. Dis. 28, 852\u2013855 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"1008_CR117","doi-asserted-by":"publisher","first-page":"e00172-17","DOI":"10.1128\/mBio.00172-17","volume":"8","author":"J Straimer","year":"2017","unstructured":"Straimer, J., Gnadig, N. F., Stokes, B. H., Ehrenberger, M., Crane, A. A. & Fidock, D. A. Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro. mBio 8, e00172-17 (2017).","journal-title":"mBio"},{"key":"1008_CR118","doi-asserted-by":"publisher","first-page":"e00605-18","DOI":"10.1128\/AAC.00605-18","volume":"62","author":"S Nair","year":"2018","unstructured":"Nair, S. et al. Fitness costs and the rapid spread of kelch13-C580Y substitutions conferring artemisinin resistance. Antimicrob. Agents Chemother. 62, e00605-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR119","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMc2117480","volume":"386","author":"BH Stokes","year":"2022","unstructured":"Stokes, B. H., Ward, K. E. & Fidock, D. A. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 386, 1385\u20131386 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1008_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2454-7","volume":"17","author":"LT Wang","year":"2018","unstructured":"Wang, L. T. et al. Private sector drug shops frequently dispense parenteral anti-malarials in a rural region of Western Uganda. Malar. J. 17, 305 (2018).","journal-title":"Malar. J."},{"key":"1008_CR121","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm.4381","volume":"23","author":"B Blasco","year":"2017","unstructured":"Blasco, B., Leroy, D. & Fidock, D. A. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat. Med. 23, 917\u2013928 (2017).","journal-title":"Nat. Med."},{"key":"1008_CR122","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1086\/507115","volume":"194","author":"AB Sidhu","year":"2006","unstructured":"Sidhu, A. B., Uhlemann, A. C., Valderramos, S. G., Valderramos, J. C., Krishna, S. & Fidock, D. A. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194, 528\u2013535 (2006).","journal-title":"J. Infect. Dis."},{"key":"1008_CR123","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/S2666-5247(21)00085-9","volume":"2","author":"PK Tumwebaze","year":"2021","unstructured":"Tumwebaze, P. K. et al. Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study. Lancet Microbe 2, e441\u2013e449 (2021).","journal-title":"Lancet Microbe"},{"key":"1008_CR124","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3201\/eid2304.161872","volume":"23","author":"BQ Phuc","year":"2017","unstructured":"Phuc, B. Q. et al. Treatment failure of dihydroartemisinin\/piperaquine for Plasmodium falciparum malaria, Vietnam. Emerg. Infect. Dis. 23, 715\u2013717 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"1008_CR125","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm, R. W. et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect. Dis. 19, 952\u2013961 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR126","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/infdis\/jiac365","volume":"226","author":"KJ Wicht","year":"2022","unstructured":"Wicht, K. J., Small-Saunders, J. L., Hagenah, L. M., Mok, S. & Fidock, D. A. Mutant PfCRT can mediate piperaquine resistance in African Plasmodium falciparum with reduced fitness and increased susceptibility to other antimalarials. J. Infect. Dis. 226, 2021\u20132029 (2022).","journal-title":"J. Infect. Dis."},{"key":"1008_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00502-9","author":"C Florimond","year":"2023","unstructured":"Florimond, C. et al. Impact of piperaquine resistance in Plasmodium falciparum on malaria treatment effectiveness in French Guiana: a descriptive epidemiological study.Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(23)00502-9 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1008_CR128","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1128\/AAC.00039-16","volume":"60","author":"R Leang","year":"2016","unstructured":"Leang, R. et al. Efficacy and safety of pyronaridine-artesunate for treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob. Agents Chemother. 60, 3884\u20133890 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR129","doi-asserted-by":"publisher","first-page":"e02242-18","DOI":"10.1128\/AAC.02242-18","volume":"63","author":"R Leang","year":"2019","unstructured":"Leang, R. et al. Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for treatment of uncomplicated Plasmodium falciparum malaria in eastern Cambodia. Antimicrob. Agents Chemother. 63, e02242-18 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR130","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/cid\/ciz580","volume":"70","author":"P Quang Bui","year":"2020","unstructured":"Quang Bui, P. et al. Pyronaridine-artesunate efficacy and safety in uncomplicated Plasmodium falciparum malaria in areas of artemisinin-resistant falciparum in Viet Nam (2017-2018). Clin. Infect. Dis. 70, 2187\u20132195 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1008_CR131","doi-asserted-by":"publisher","first-page":"e01273-19","DOI":"10.1128\/AAC.01273-19","volume":"63","author":"R Leang","year":"2019","unstructured":"Leang, R. et al. Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for the treatment of malaria in western Cambodia. Antimicrob. Agents Chemother. 63, e01273-19 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR132","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4269\/ajtmh.21-1095","volume":"106","author":"M Rahi","year":"2022","unstructured":"Rahi, M., Chaturvedi, R., Goswami, R. & Sharma, A. India needs to consider planning a change to artemether-lumefantrine to treat Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 106, 1305\u20131310 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR133","doi-asserted-by":"publisher","first-page":"e01949-20","DOI":"10.1128\/AAC.01949-20","volume":"65","author":"PR Dimbu","year":"2021","unstructured":"Dimbu, P. R. et al. Continued low efficacy of artemether-lumefantrine in Angola in 2019. Antimicrob. Agents Chemother. 65, e01949-20 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR134","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.4269\/ajtmh.21-0214","volume":"105","author":"LF Moriarty","year":"2021","unstructured":"Moriarty, L. F. et al. Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. Am. J. Trop. Med. Hyg. 105, 1067\u20131075 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03585-6","volume":"20","author":"A Gansane","year":"2021","unstructured":"Gansane, A. et al. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018. Malar. J. 20, 48 (2021).","journal-title":"Malar. J."},{"key":"1008_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-04021-5","volume":"20","author":"C Ebong","year":"2021","unstructured":"Ebong, C. et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar. J. 20, 484 (2021).","journal-title":"Malar. J."},{"key":"1008_CR137","doi-asserted-by":"publisher","first-page":"e00220-21","DOI":"10.1128\/AAC.00220-21","volume":"65","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen, C. & Ringwald, P. Continued low efficacy of artemether-lumefantrine in Angola? Antimicrob. Agents Chemother. 65, e00220-21 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1008_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03845-5","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen, C. & Ringwald, P. Is there evidence of anti-malarial multidrug resistance in Burkina Faso? Malar. J. 20, 320 (2021).","journal-title":"Malar. J."},{"key":"1008_CR139","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.pt.2022.08.005","volume":"38","author":"IM Hastings","year":"2022","unstructured":"Hastings, I. M. & Felger, I. WHO antimalarial trial guidelines: good science, bad news? Trends Parasitol. 38, 933\u2013941 (2022).","journal-title":"Trends Parasitol."},{"key":"1008_CR140","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.4269\/ajtmh.20-1481","volume":"104","author":"MM Plucinski","year":"2021","unstructured":"Plucinski, M. M., Hastings, I. M., Moriarty, L. F., Venkatesan, M., Felger, I. & Halsey, E. S. Variation in calculating and reporting antimalarial efficacy against Plasmodium falciparum in sub-Saharan Africa: a systematic review of published reports. Am. J. Trop. Med. Hyg. 104, 1820\u20131829 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1008_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02652-2","volume":"20","author":"DM Wakoli","year":"2022","unstructured":"Wakoli, D. M. et al. Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs. BMC Med. 20, 448 (2022).","journal-title":"BMC Med."},{"key":"1008_CR142","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/IDR.S295277","volume":"14","author":"MF Ofori","year":"2021","unstructured":"Ofori, M. F. et al. Ex vivo sensitivity Profile of Plasmodium falciparum clinical isolates to a panel of antimalarial drugs in Ghana 13 years after national policy change. Infect. Drug. Resist. 14, 267\u2013276 (2021).","journal-title":"Infect. Drug. Resist."},{"key":"1008_CR143","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40268-020-00313-4","volume":"20","author":"K Traore","year":"2020","unstructured":"Traore, K. et al. Ex-vivo sensitivity of Plasmodium falciparum to common anti-malarial drugs: the case of Kenieroba, a malaria endemic village in Mali. Drugs R. D. 20, 249\u2013255 (2020).","journal-title":"Drugs R. D."},{"key":"1008_CR144","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm, R. W. et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet 395, 1345\u20131360 (2020).","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1038\/s41579-024-01032-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000}}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-024-01008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-024-01008-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-024-01008-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T09:07:28Z","timestamp":1715936848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-024-01008-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1038\/s41579-024-01008-2","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"2 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41579-024-01032-2","URL":"https:\/\/doi.org\/10.1038\/s41579-024-01032-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}